Advertisement

Topics

As the IDO Battle Gets Ugly, Bristol-Myers Shows Off Early Data for Combo Trial

19:00 EST 9 Nov 2017 | BioSpace

First disclosure of anti-tumor activity from the bladder and cervical cancer cohorts showed objective response rates of 32% and 14%, respectively, and was 46% and 25% in patients who express PD-L1 ≥1%.

Original Article: As the IDO Battle Gets Ugly, Bristol-Myers Shows Off Early Data for Combo Trial

NEXT ARTICLE

More From BioPortfolio on "As the IDO Battle Gets Ugly, Bristol-Myers Shows Off Early Data for Combo Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bladder Cancer
Non-invasive bladder cancer is a cancer that is only in the inner lining of the bladder. Invasive bladder cancer is cancer that has spread into the deeper walls of the bladder. When the cancer has spread outside the bladder to other parts of the body, th...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...